Equity · Healthcare
BEAM
NASDAQBeam Therapeutics (BEAM)
The line runs 27 USD on 11 August through 26.41 USD on 6 November, on a scale from 22.5 to 32.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 2.7B USD
- Revenue, year to Dec 2025
- 139.7M USD
- EPS, diluted, year to Dec 2025
- −0.81 USD
- 52-week range
- 20.60 USD – 37.96 USD
- Avg volume
- 95.1K
as of Nov 6, 2026
Have Beam Therapeutics (BEAM) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Beam Therapeutics insiders reported 3 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 6 Oct 2025, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 16 Oct 2026
Buys 0Sells 3Net sold $1.19MOther filings 3
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 16 Oct 2026 | Evans John M.CEO | Sell | 25,000 | 600K USD |
| 15 Oct 2026 | Evans John M.CEO | Sell | 25,000 | 589K USD |
| 01 Oct 2026 | Cavanagh Bethany JSVP, Finance and Treasurer | Sell | 187 | 5K USD |
| Sold | 3 open-market sales | 50,187 | $1.19M |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 16 Oct 2026 | Evans John M.CEO | Option exercise | 25,000 | 26K USD |
| 15 Oct 2026 | Evans John M.CEO | Option exercise | 25,000 | 26K USD |
| 24 Sep 2026 | Ciaramella GiuseppePresident | Gift | 123,407 |
Which funds hold Beam Therapeutics (BEAM)?
11 of the 45 institutional funds we track reported a Beam Therapeutics position for the quarter ended 30 Jun 2026 — a combined 449.8M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| ARK Investment Management | Held (±25%) | 10,234,862 | 351.3M USD | −15.6% |
| Two Sigma Investments | Held (±25%) | 1,388,227 | 47.6M USD | +14.6% |
| Marshall Wace | Added | 478,980 | 16.4M USD | +244.0% |
| Renaissance Technologies | Held (±25%) | 445,000 | 15.3M USD | −13.4% |
| Duquesne Family Office | New position | 153,600 | 5.3M USD | |
| D. E. Shaw & Co. | New position | 130,577 | 4.5M USD | |
| Man Group | Trimmed | 129,820 | 4.5M USD | −44.0% |
| Tudor Investment Corp | Held (±25%) | 49,092 | 1.7M USD | +3.8% |
| Balyasny Asset Management | New position | 41,792 | 1.4M USD | |
| Millennium Management | Added | 34,260 | 1.2M USD | +54.1% |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
What has been filed or recorded for Beam Therapeutics (BEAM)?
The filings we hold for Beam Therapeutics, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 6,331 shares | 159K USD notional · 0.006% of shares out |
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 363 shares | 9K USD notional · <0.001% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 5,198 shares | 127K USD notional · 0.005% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.28 USD | |
| 30 Sep 2026 | Financials | Total assets | 1.3B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 952.7M USD | at period end |
| 28 Sep 2026 | Fails to deliver | Shares failed to deliver | 1,512 shares | 37K USD notional · 0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.18 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.91 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.81 USD | |
| 31 Dec 2025 | Financials | Revenue | 139.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −80.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.81 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.10 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −1.00 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.23 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −4.58 USD |
Beam Therapeutics (BEAM): frequently asked questions
What did Beam Therapeutics shares close at?
Beam Therapeutics closed at 26.41 USD on 6 Nov 2026, up 2.36% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Beam Therapeutics’ market cap?
Beam Therapeutics is worth 2.7B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Beam Therapeutics’ revenue?
Beam Therapeutics reported revenue of 139.7M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Beam Therapeutics insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Beam Therapeutics insiders reported 3 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 6 Oct 2025, show no open-market purchase. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Beam Therapeutics?
11 of the 45 funds we track reported a Beam Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were ARK Investment Management, Two Sigma Investments and Marshall Wace. See Funds
When did Beam Therapeutics last report earnings?
Beam Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.28 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings